Insider Trading May 5, 2026 07:28 PM

Aeluma CEO Executes $499,000 Stock Sale via Pre-Set Trading Plan

Executive Jonathan Klamkin liquidates 20,000 shares amid significant recent price appreciation and new government contract wins.

By Nina Shah ALMU

Jonathan Klamkin, the Chief Executive Officer of Aeluma, Inc. (NASDAQ: ALMU), has completed a sale of common stock totaling $499,272. The transactions, which took place on May 1, 2026, involved the disposal of 20,000 shares at various price points ranging from $23.62 to $26.02 per share. These sales were conducted under a Rule 10b5-1 trading plan that was originally established by Mr. Klamkin on December 3, 2025.The divestment occurs during a period of notable volatility and upward momentum for Aeluma shares. At the time of reporting, the stock was trading at $27.38, positioned near its 52-week high of $28.39, following a substantial increase of 44.76% over the preceding week. Despite this recent rally, valuation metrics suggest potential tension between market price and intrinsic value; analysis indicates the stock may be overvalued relative to its Fair Value, currently trading at a Price/Book multiple of 10.13 for the company, which maintains a market capitalization of $413 million.

Aeluma CEO Executes $499,000 Stock Sale via Pre-Set Trading Plan
ALMU

Key Points

  • <strong>Insider Divestment via Structured Plan:</strong> CEO Jonathan Klamkin sold 20,000 shares totaling nearly $500,000 through a Rule 10b5-1 plan established in late 2025. This impacts the semiconductor and specialty finance sectors by signaling executive liquidity moves within a period of high stock performance.
  • <strong>Governmental and Research Momentum:</strong> Aeluma has secured over $4 million in U.S. Government contracts and an award from NASA for quantum dot laser development, impacting the defense, aerospace, and AI infrastructure sectors.
  • <strong>Capital Flexibility and Valuation Metrics:</strong> The company established a $50 million at-the-market equity sales agreement, providing liquidity options while trading at a high Price/Book multiple of 10.13, which may influence semiconductor market valuation models.

Aeluma, Inc. (NASDAQ: ALMU) saw significant insider activity on May 1, 2026, when Chief Executive Officer Jonathan Klamkin sold 20,000 shares of common stock. The total value of these transactions amounted to $499,272. To ensure compliance and structured execution, the sales were carried out through a Rule 10b5-1 trading plan that Mr. Klamkin had adopted on December 3, 2025.


Detailed Breakdown of Share Disposals

The sale of the 20,000 shares was executed in three distinct transaction blocks, each with different pricing structures:

  • First Block: A total of 4,300 shares were sold at a weighted average price of $24.1992 per share. The individual prices for these specific sales fluctuated between $23.62 and $24.61.
  • Second Block: An additional 15,024 shares were transacted at a weighted average price of $25.1487 per share, with the price range for this group falling between $24.62 and $25.61.
  • Third Block: The final segment consisted of 676 shares sold at a weighted average price of $25.7125 per share, with individual prices ranging from $25.62 to $26.02.

Estate Planning and Indirect Ownership

In addition to the market sales, regulatory filings highlighted several non-market transfers of common stock involving Mr. Klamkin and a family trust. In December 2025, Mr. Klamkin moved 1,476,995 shares into a family trust for the purposes of estate planning. Both Mr. Klamkin and his spouse serve as the sole trustees of this entity. Following that initial transfer, several subsequent movements occurred between direct ownership and the trust without reported monetary value: on March 4, 2026, 50,000 shares were transferred; on April 1, 2026, 20,000 shares were moved; and on May 1, 2026, another 20,000 shares were transferred. Following these various transactions, Mr. Klamkin's direct holdings consist of 2,403 shares, while the family trust holds an indirect total of 1,386,995 shares.


Operational Developments and Strategic Funding

The insider activity coincides with a series of high-profile business milestones for Aeluma. The company recently announced it had secured more than $4 million in contracts from the U.S. Government. These funds are intended to advance the company's semiconductor heterogeneous integration platform, which is designed for applications in high-speed data communication and quantum technologies. This initiative involves collaboration with Sumitomo Chemical Advanced Technology and Tower Semiconductor regarding fabrication and wafer production.

Furthermore, Aeluma has been granted an award from NASA to progress its integrated quantum dot laser platform. This project focuses on enhancing sensing and data communication applications, specifically targeting the development of quantum dot lasers for use in AI data center interconnects. On the capital side, Aeluma has entered into a $50 million at-the-market equity sales agreement with several firms, including Roth Capital Partners. This agreement grants the company the flexibility to offer and sell common stock at various times and prices, though there is no obligation for the firm to execute these sales.


Market Position and Executive Changes

The semiconductor sector's interest in Aeluma is evidenced by recent analyst activity. Freedom Capital Markets initiated coverage on the company with a buy rating, pointing toward the cost-reduction benefits of Aeluma's proprietary heteroepitaxy process for SWIR sensors. Additionally, the company has strengthened its leadership team by appointing Willy Rachmady, Ph.D., a former executive from Intel, as the new Vice President of Strategic Partnerships and Ecosystem.

Risks

  • <strong>Valuation Discrepancy:</strong> The stock is currently trading near its 52-week high and appears overvalued relative to its Fair Value based on current Price/Book multiples, posing a risk to investors in the technology and semiconductor sectors.
  • <strong>Equity Dilution Potential:</strong> While providing flexibility, the $50 million at-the-market equity sales agreement allows for the issuance of new shares, which could impact shareholder value within the specialty finance and equity markets.

More from Insider Trading

SentinelOne CEO Executes $3.55 Million Stock Sale Under Rule 10b5-1 Plan May 5, 2026 Axsome Therapeutics COO Executes $1.08 Million Stock Sale via Pre-Planned Trading Program May 5, 2026 Arcutis Biotherapeutics Director Executes Stock Sale via Pre-Arranged Plan May 5, 2026 Amgen Executive Nancy Grygiel Executes Recent Stock Transactions May 5, 2026 Privia Health CFO Executes Stock Sales Totaling Over $200,000 via Rule 10b5-1 Plan May 5, 2026